We are delighted to announce that one of our clients, CTI BioPharma, has received FDA accelerated approval for VONJO™ (pacritinib), for the treatment of adult patients with myelofibrosis and thrombocytopenia. Pacritinib is a macrocyclic small molecule oral kinase inhibitor with activity against Janus Associated Kinase2 (JAK2), mutant JAK2V617F as well as the FMS-like tyrosine kinase 3 …
>> Read more